Quarterly ResultMay 14, 2026, 04:38 PM
SpyGlass Pharma Completes $172.5M IPO; Q1 Net Loss $13.8M
AI Summary
SpyGlass Pharma, Inc. completed its initial public offering on February 9, 2026, raising $172.5 million in gross proceeds. This significantly boosted the company's cash position to $238.9 million by March 31, 2026. For the first quarter of 2026, the company reported a net loss of $13.8 million, an increase from $8.8 million in the prior year, driven by higher R&D and G&A expenses. SpyGlass Pharma is a late-stage biopharmaceutical company that has initiated Phase 3 clinical trials for its lead product, the Bimatoprost Drug Pad-IOL System, for glaucoma treatment.
Key Highlights
- Completed IPO on February 9, 2026, raising $172.5 million in gross proceeds.
- Cash and cash equivalents increased to $238.9 million as of March 31, 2026, from $96.4 million at year-end 2025.
- Reported a net loss of $13.8 million for Q1 2026, compared to $8.8 million for Q1 2025.
- Research and development expenses rose to $8.5 million in Q1 2026 from $6.1 million in Q1 2025.
- General and administrative expenses increased to $6.9 million in Q1 2026 from $1.4 million in Q1 2025.
- Initiated Phase 3 clinical trials for its lead product, the Bimatoprost Drug Pad-IOL System, for glaucoma.
- Management believes existing liquidity is sufficient to continue as a going concern for the next twelve months.
- All outstanding redeemable convertible preferred stock converted to common stock upon IPO.